ScreenerHero

MBIO Mustang Bio, Inc.

NAS · US · Healthcare · Biotechnology · mustangbio.com
0.4502USD-2.13%Mkt Cap: 3.41M $P/E: —

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.41M USD
Enterprise Value-11.66M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-1.92M USD
Revenue/Share—
Last Price0.4502 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.31
PEG—
EV/EBITDA3.33
EV/Revenue—
P/S—
P/B0.46
EPS (TTM)-0.44
EPS (Forward)-0.35
52W Range
0.45000% of range1.850
52W High1.850 USD
52W Low0.4500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-20.16%
ROA-10.92%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.26M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-125.23%
Net Debt-15.15M USD
Net Debt/EBITDA4.32
Balance Sheet
Debt/Equity0.00
Current Ratio1.97
Quick Ratio1.94
Book Value/Sh1.00 USD
Cash/Share2.00 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateJan 16, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.6.73M
Float6.19M
Insiders8.02%
Institutions9.93%
Short Interest
Short Ratio3.0d
Short % Float0.87%
Short % Out.0.77%
Shares Short58.51K
Short (prev mo.)52.57K
Technical
SMA 500.5474 (-17.8%)
SMA 2000.7517 (-40.1%)
Beta2.09
S&P 52W Chg16.45%
Avg Vol (30d)23.95K
Avg Vol (10d)24.31K
Technical Indicators
RSI (14)30.5
MACD-0.0287
MACD Signal-0.0253
MACD Hist.-0.0034
BB Upper0.5650 USD
BB Middle0.5024 USD
BB Lower0.4397 USD
BB Width24.93%
ATR (14)0.0254 USD
Vol Ratio (20d)0.63x